H.C. Wainwright reiterates Protalix BioTherapeutics Inc. [PLX] at Buy and assigns price target at $11
H.C. Wainwright maintained its Protalix BioTherapeutics Inc. [AMEX:PLX] rating to the equivalent of Buy but changed the price target to $11, in a research note dated December 31, 2020. That figure represents around a 212.5% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with H.C. Wainwright’s analysts reiterating […]
